Home
 

Pharmacy Benefits Management

 
March 12, 2015 | Anthony Brino

Health insurers and American consumers might be spending more than ever for prescription drugs, but there are also more choices and more information to find value in a sea of volume.


March 9, 2015 | Anthony Brino

An increasingly popular strategy in drug plan affordability is again coming under scrutiny from Medicare regulators concerned that some urban seniors are being left out.


March 6, 2015 | Anthony Brino

Health insurers and patients could get a bit of relief after years of paying more and more for biologic speciality pharmaceuticals, but some think there are still barriers to affordability.


March 4, 2015 | Anthony Brino

Middle-age American men have been aggressively marketed treatments for low testosterone, despite risks and skepticism about benefits. Now insurers have another reason to strictly control coverage.


February 11, 2015 | Anthony Brino

The country's fourth largest drugstore chain is making a $2 billion bet on the business of pharmaceutical benefits management, amid rising drug prices and demand for retail consumer healthcare.


February 4, 2015 | Anthony Brino

With the surging costs of specialty drugs, what was once unthinkable in American healthcare is starting to look like a viable idea that the President is pushing.


January 29, 2015 | Anthony Brino

Insurers have to improve consumer education about drug formularies in exchanges, at the least, and some may even have to change their practices to meet new health reform standards.


January 22, 2015 | Anthony Brino

The nation's third largest insurer is the latest to find a cheaper way to bring a curative therapy to members with Hepatitis C.


January 14, 2015 | Anthony Brino

If 2014 was a year of managing member populations who need a blockbuster treatment for hepatitis C, 2015 is turning out to be one of deals for everyone to access that drug.


January 8, 2015 | Anthony Brino

More affordability may be coming to the surging speciality pharmaceuticals space, as regulators move to approve the first generic-equivalent version of a biologic drug.


January 7, 2015 | Anthony Brino

Competition for treating America's hepatitis C population is intensifying among pharmaceutical companies and benefits management firms, suggesting a thaw in the $1,000 per-pill price of last year's blockbuster.


December 22, 2014 | Anthony Brino

In the war for affordably treating the hepatis C liver virus, pharmacy benefits managers are fighting back now that alternatives are becoming available.


Advertisement. Closing in 15 seconds.